A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading to its approval. This study investigated the efficacy and safety of sarilumab (another IL-6Ri) in GCA.
METHODS: This Phase 3, double-blind study comprised a 52-week treatment period and a 24-week follow-up phase. Eligible GCA patients were randomized to receive sarilumab 200 mg (SAR200 + 26W) or 150 mg (SAR150 + 26W) with a 26-week GC taper, or placebo with a 52-week (PBO + 52W) or 26-week (PBO + 26W) GC taper. The primary efficacy endpoint was sustained remission (SR) at week 52. Additional endpoints were SR at week 24, cumulative GC dose, and safety. The study was discontinued prematurely due to protracted recruitment timelines, because of the impact of COVID-19. Therefore, only descriptive statistics were summarized.
RESULTS: Of the planned 360 subjects, only 83 were randomized and 36 were included in the week 52 analysis. At week 52, 46% (n = 6/13) of patients in SAR200 + 26W, 43% (n = 3/7) in SAR150 + 26W, 30% (n = 3/10) in PBO + 52W, and 0 (n = 0/6) in PBO + 26W taper groups achieved SR. Sensitivity analyses, excluding acute-phase reactants from the SR definition, showed similar results for SAR groups, but 60% (n = 6/10) in PBO + 52W and 17% (n = 1/6) in PBO + 26W taper groups achieved SR at week 52. Similar findings were noted at week 24. The proportions of patients who adhered to GC taper from week 12 through week 52 in each group were as follows: 46% (n = 6/13, SAR200 + 26W), 43% (n = 3/7, SAR150 + 26W), 60% (n = 6/10, PBO + 52W), and 33% (n = 2/6, PBO + 26W). The median actual cumulative GC dose received in the SAR200 + 26W group was lower than other groups. Most patients (80-100%) experienced treatment-emergent adverse events, with similar incidences reported across groups.
CONCLUSIONS: Owing to the small sample size due to the early termination, it is difficult to draw clear conclusions from this study. There were no unexpected safety findings.
TRIAL REGISTRATION: ClinicalTrials.gov NCT03600805. Registered on July 26, 2018.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Arthritis research & therapy - 25(2023), 1 vom: 16. Okt., Seite 199 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schmidt, Wolfgang A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial, Phase III |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 21.11.2023 published: Electronic ClinicalTrials.gov: NCT03600805 Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13075-023-03177-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363329803 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363329803 | ||
| 003 | DE-627 | ||
| 005 | 20231226093121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13075-023-03177-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363329803 | ||
| 035 | |a (NLM)37840134 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schmidt, Wolfgang A |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03600805 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
| 520 | |a BACKGROUND: Giant cell arteritis (GCA) is primarily treated with glucocorticoids (GCs), which have substantial toxicity. Tocilizumab, an interleukin-6-receptor inhibitor (IL-6Ri), showed beneficial effects in GCA, leading to its approval. This study investigated the efficacy and safety of sarilumab (another IL-6Ri) in GCA | ||
| 520 | |a METHODS: This Phase 3, double-blind study comprised a 52-week treatment period and a 24-week follow-up phase. Eligible GCA patients were randomized to receive sarilumab 200 mg (SAR200 + 26W) or 150 mg (SAR150 + 26W) with a 26-week GC taper, or placebo with a 52-week (PBO + 52W) or 26-week (PBO + 26W) GC taper. The primary efficacy endpoint was sustained remission (SR) at week 52. Additional endpoints were SR at week 24, cumulative GC dose, and safety. The study was discontinued prematurely due to protracted recruitment timelines, because of the impact of COVID-19. Therefore, only descriptive statistics were summarized | ||
| 520 | |a RESULTS: Of the planned 360 subjects, only 83 were randomized and 36 were included in the week 52 analysis. At week 52, 46% (n = 6/13) of patients in SAR200 + 26W, 43% (n = 3/7) in SAR150 + 26W, 30% (n = 3/10) in PBO + 52W, and 0 (n = 0/6) in PBO + 26W taper groups achieved SR. Sensitivity analyses, excluding acute-phase reactants from the SR definition, showed similar results for SAR groups, but 60% (n = 6/10) in PBO + 52W and 17% (n = 1/6) in PBO + 26W taper groups achieved SR at week 52. Similar findings were noted at week 24. The proportions of patients who adhered to GC taper from week 12 through week 52 in each group were as follows: 46% (n = 6/13, SAR200 + 26W), 43% (n = 3/7, SAR150 + 26W), 60% (n = 6/10, PBO + 52W), and 33% (n = 2/6, PBO + 26W). The median actual cumulative GC dose received in the SAR200 + 26W group was lower than other groups. Most patients (80-100%) experienced treatment-emergent adverse events, with similar incidences reported across groups | ||
| 520 | |a CONCLUSIONS: Owing to the small sample size due to the early termination, it is difficult to draw clear conclusions from this study. There were no unexpected safety findings | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.gov NCT03600805. Registered on July 26, 2018 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Giant cell arteritis | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 4 | |a Interleukin-6 | |
| 650 | 4 | |a Sarilumab | |
| 650 | 4 | |a Sustained remission | |
| 650 | 7 | |a sarilumab |2 NLM | |
| 650 | 7 | |a NU90V55F8I |2 NLM | |
| 700 | 1 | |a Dasgupta, Bhaskar |e verfasserin |4 aut | |
| 700 | 1 | |a Sloane, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Giannelou, Angeliki |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Unizony, Sebastian H |e verfasserin |4 aut | |
| 700 | 1 | |a Mackie, Sarah L |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Gay, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Spiera, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Warrington, Kenneth J |e verfasserin |4 aut | |
| 700 | 1 | |a Villiger, Peter M |e verfasserin |4 aut | |
| 700 | 1 | |a Nivens, Michael C |e verfasserin |4 aut | |
| 700 | 1 | |a Akinlade, Bolanle |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Buttgereit, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, John H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis research & therapy |d 2003 |g 25(2023), 1 vom: 16. Okt., Seite 199 |w (DE-627)NLM124870457 |x 1478-6362 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:1 |g day:16 |g month:10 |g pages:199 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13075-023-03177-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 1 |b 16 |c 10 |h 199 | ||